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ABSTRACT
Background: There is evidence that neutrophils are increased in the airway of severe disease or acute exac-
erbations of asthma. The mechanisms by which neutrophils are recruited to the airways and contribute to the
pathophysiology of asthma remain to be elucidated. Tumor necrosis factor (TNF-α), which can induce both tis-
sue accumulation and activation of neutrophils and eosinophils, has been shown to be increased in the airways
of severe asthma. The objective of this study is to evaluate whether TNF-α is associated with neutrophilic in-
flammation in asthma.
Methods: Following an inhalation of hypertonic saline, induced sputum was obtained from 9 healthy controls,
9 mild persistent asthma patients who were treated with low-dose inhaled corticosteroids; and 7 severe persis-
tent asthma patients who were treated with combinations of drugs including high-dose inhaled corticosteroids,
oral prednisolone, bronchodilators, and leukotriene receptor antagonist. After 0.1% dithiothreitol (DTT) homog-
enization, they were examined for total cell count, cellular differentiation, and the concentrations of TNF-α and
myeloperoxidase (MPO).
Results: The concentration of TNF-α was not correlated with neutrophils in healthy controls or mild asthma
patients. In sputum from severe asthma patients, however, the concentration of TNF-α is significantly corre-
lated with both the percentage of neutrophils and the concentration of MPO. The concentration of TNF-α is not
correlated with the percentage of eosinophils in healthy controls, mild asthma patients, or severe asthma pa-
tients.
Conclusions: TNF-α may be a contributing molecule for both accumulation and activation of neutrophils in
the airways of severe asthma.
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INTRODUCTION
Asthma is a complex syndrome, characterized by air-
flow limitation, bronchial hyperresponsiveness, and
chronic inflammation . In general , inflammation in
asthma is characterized by accumulations of eosino-
phils, lymphocytes, and mast cells in the bronchial
tissue. 1,2 It has been recently shown that neutrophils
also accumulate in the airways of asthma patients
with severe disease 3-5 and during acute exacerba-
tion.6 The mechanisms by which neutrophils are re-
cruited to the airways and contribute to the patho-
physiology of asthma remains to be elucidated. Tu-
mor necrosis factor (TNF-α), which can induce both
tissue accumulation and activation of neutrophils, has
been shown to be increased in the airways of severe
asthma.7 TNF-α is capable of enhancing the expres-
sion of intercellular adhesion molecule ( ICAM) -1
generating CXC chemokines such as IL-8 from endo-
thelial cells8,9 and thereby augmenting neutrophilic
inflammation. Moreover, TNF-α can directly induce
activation of neutrophils.10-12 Therefore, it is reason-
able to postulate that TNF-α may be involved in neu-
trophilic inflammation in the airways of asthma pa-
tients. In this study we report that the concentration
of TNF-α is associated with both the accumulation
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Table 1 Patient characteristics I 
Severe
asthma patients
(n＝7) 
Mild asthma patients
(n＝9) 
Healthy
(n＝9) 
(5/2) (4/5) (6/3) Gender (M/F) 
 54.4 ± 4.2 42.3 ± 5.8  31.9 ± 2.0*Age (years) 
 5.4 ± 1.8  4.4 ± 1.0  3.4 ± 0.6 Sputum volume (mL) 
 19.2 ± 8.8 20.9 ± 4.7  22.3 ± 6.1 Total sputum cels (105/mL) 
 29.8 ± 10.1 27.1 ± 8.5  20.1 ± 6.3 Squamous epithelium (%) 
 3.1 ± 1.2** 7.2 ± 4.4  0.2 ± 0.1 Sputum eosinophils (%) 
*p＜0.05 vs others　**p＜0.01 vs healthy 
Table 2 Patient characteristics I 
Severe asthma patients (n＝7) Mild asthma patients (n＝9) 
 63.1 ± 11.9* 79.5 ± 2.5%FEV1.0
 17.4 ± 5.5  15.4 ± 3.2Disease duration (yrs) 
 839.9 ± 430.0 3114.5 ± 1772.5 IgE (IU/ml) 
Positive case of IgE Ab:
5 (71.4%) 6 (66.7%) D. farinae
4 (57.1%) 7 (77.8%) C. albicance
6 (85.7%) 9 (100.0%)J. cedar
*p＜0.05 vs mild asthma patients
and the activation of neutrophils in sputum from pa-
tients with severe persistent asthma.
METHODS
PATIENTS
The study population consisted of 16 asthma patients
recruited from the Department of Respiratory Medi-
cine, Saitama Medical School Hospital, and 9 healthy
controls. Subjects who had an episode of cold syn-
drome during the last four weeks prior to the onset of
this study were excluded. In addition, subjects who
showed positive c-reactive protein at the time of sam-
pling were excluded. Consequently, the number of
healthy controls was 9, and the numbers of patients
who were enrolled in this study were as follows: 9
mild persistent asthma patients; and 7 severe persis-
tent asthma patients (Table 1). Asthma was diag-
nosed based on a history of recurrent wheezing ,
dyspnea, chest tightness, and either reversible air-
flow limitation (forced expiratory volume in one sec-
ond (FEV1): <70% predicted or previous best, which
increased by >15% after the inhalation of 200 μg salbu-
tamol) or methacholine-induced airway hyperrespon-
siveness. Asthma patients were assigned into the fol-
lowing two groups: a group of 9 patients with mild
persistent (step 2) asthma treated with 200 μg flutica-
sone dipropionate dry powder inhaler ( FP-DPI )
alone; and another group of 7 patients with severe
persistent (step 4) asthma treated with a combination
of 800 μg FP-DPI, a long-acting beta agonist inhaled
salmeterol, theophylline, leukotriene receptor antago-
nist (LTRA), and 5 to 10 mg oral prednisolone.
SPUTUM INDUCTION AND PROCESSING
Sputum was induced with an aerosol of hypertonic sa-
line according to a method described in previous arti-
cles.13,14 Informed consent was obtained prior to col-
lection of each sputum sampling. Inhaled salbutamol
was administered with a metered dose inhaler at 15
minutes before sputum induction. Subsequently, the
patient inhaled 3.5% saline nebulized by an ultrasonic
nebulizer at room temperature . The total time for
sputum induction was 15 minutes . Mouth washing
before each cough was encouraged to minimize sali-
vary contamination. The initial sample from the first
cough was discarded. Induced sputum was collected
into a 50-mL polypropylene tube, kept at 4℃ , and
processed within 2 hours after collection. To process
induced sputum, 1 ml of Hank’s balanced salt solu-
tion (HBSS) containing 0.1% dithiothreitol (DTT)
(purchased from Sigma, St. Louis, MO, USA) was
added to the 1 ml sputum. The mixture was vortexed
and repeatedly aspirated at ambient temperature until
the sputum was homogenized. Samples were further
diluted with HBSS to 5 mL, and centrifuged at 400 xg
for 10 minutes. Cell pellets were resuspended, and
slides were prepared using Cytospin and stained with
May-Giemsa for differential cell counts. At least 500
inflammatory cells were counted for each sample. An
adequate sample was defined as having less than 50%
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Fig. 1 The percentages of neutrophils (A) and concentrati-
ons of TNF-α (B) in sputum from normal volunteers (n＝9), 
mild asthma patients (n＝ 9), and severe asthma patients 
(n＝7). Data are expressed as means＋/－SEM.
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Fig. 2 Relationship between sputum TNF-α and neutro-
phils in mild asthma patients (A), and severe asthma pa-
tients (B). (A): p＞0.1, （B）: p＜0.05, r＝0.68.
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of squamous epithelial cells on Cytospin.
CONCENTRATIONS OF TNF-α AND MPO IN SPU-
TUM
The concentrations of TNF-α and MPO in the super-
natants of sputum were determined by ELISA kits
(TNF-α ; R&D systems , Minneapolis , MN, USA ,
MPO; CALBIOCHEM, San Diego, CA, USA).
STATISTICS
In order to determine statistical significance , the
Kruskal-Wallis test was conducted. A value of p < 0.05
was considered to indicate a statistically significant
difference. Data are shown as means ± SEM. Simi-
larly, Spearman’s correlation test was conducted in
order to determine statistical correlation.
RESULTS
Age was significantly lower in healthy controls than
in both asthma groups and the percentage of eosino-
phils in induced sputum was significantly higher in
severe asthma patients than in healthy controls (Ta-
ble 1) . There was no significant difference among
these three groups with respect to gender distribu-
tion, induced sputum volume, total number of sputum
inflammatory cells, and squamous epithelium (Table
1). There was no significant difference between the
two asthma groups with respect to disease duration,
total IgE, positive rate of specific IgE to house-dust
mite, candida albicans, or Japanese cedar. However,
%FEV1.0 was significantly lower in severe asthma pa-
tients (Table 2). The percentage of neutrophils in in-
duced sputum was significantly higher in severe
asthma patients than in mild asthma patients (p <
0.05; Fig. 1A). However, there was no significant dif-
ference between healthy controls and mild asthma
patients (Fig. 1A). There was no significant difference
between the three groups with respect to the concen-
tration of sputum TNF-α (p > 0.1, respectively; Fig. 1
B).
We next evaluated whether there was an associa-
tion between the concentration of TNF-α and percent-
ages of neutrophils or eosinophils in sputum. There
was no significant correlation between sputum TNF-α
and neutrophils in the mild asthma group (p > 0.1,
Fig. 2A) or healthy control subjects (p > 0.1, data not
shown) . On the other hand , in severe persistent
asthma patients, there was a significant positive cor-
relation between TNF-α and percentage of neutro-
phils in sputum (p < 0.05, r = 0.68 ; Fig. 2B). There
was no significant correlation between TNF-α and
percentages of eosinophils in healthy controls, mild
asthma patients, or severe asthma patients (p > 0.1,
respectively, data not shown).
Finally we evaluated whether there was an associa-
tion between concentrations of TNF-α and MPO in
sputum. In mild asthma patients, there was no signifi-
cant correlation between sputum TNF-α and MPO
(p > 0.1, Fig. 3A). On the other hand, there was a sig-
nificant positive correlation between the concentra-
tion of TNF-α and MPO in sputum in severe persis-
tent asthma patients (p < 0.05, r = 0.93; Fig. 3B). Such
a positive correlation between TNF-α and MPO was
also observed in healthy control subjects (p < 0.01, r =
0.50; data not shown).
DISCUSSION
We observed that severe asthma patients showed sig-
nificantly higher sputum neutrophilia than mild
asthma populations. It is noteworthy that these pa-
tients were treated with a combination of oral and
high dose inhaled corticosteroids. There is evidence
that corticosteroids are not capable of suppressing
the tissue accumulation or functions of neutro-
phils,15,16 suggesting that neutrophils recruited to the
airways in severe asthma may still play a role. For ex-
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Fig 3 Relationship between sputum TNF-α and MPO in 
mild asthma patients (A), and severe asthma patients (B). 
(A): p＞0.1, （B）: p＜0.05, r＝0.93.
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ample, neutrophils are capable of producing chemoat-
tractants for eosinophils such as leukotriene B4 and
releasing proteases including matrix metalloprotease
(MMP) and elastase which can cause tissue injury15
and hence may contribute to the deterioration of se-
vere asthma. On the other hand, there was only a
trend, but no significant difference, in the percent-
ages of sputum neutrophils between severe asthma
and healthy subjects. Although the reason for this re-
mains to be clarified, the lack of difference between
these two groups is attributable, at least in part, to the
small size of this study. In asthma, association be-
tween age and neutrophilic inflammation seems con-
troversial.17,18 Although the mean age of controls was
younger than that of the two asthma groups in our
study, it is unclear that this fact adversely affects the
interpretation of this study because these subjects
are healthy individuals without manifestation of
asthma. Furthermore, there was no difference in age
between the two asthma groups in our study.
It is of particular interest that the concentration of
sputum TNF-α is positively correlated with the airway
accumulation of neutrophils in severe persistent asth-
matics. Furthermore, we found that concentration of
TNF-α is correlated with MPO in severe asthma pa-
tients. TNF-α is capable of enhancing the expression
of intercellular adhesion molecule (ICAM) -1 on and
generation of chemokines from endothelial cells 8,9
and thereby can augment neutrophilic inflammation.
Moreover, TNF-α can directly induce adhesion and
activation of neutrophils.10-12 In the airways of severe
asthma patients, contributing mechanisms of TNF-α
may be augmented in the presence of other inflam-
matory molecules. Therefore, it is theoretically plau-
sible that TNF-α contributes to both accumulation
and activation of neutrophils in the airways of severe
asthma patients, which persists even under full corti-
costeroid therapy. In contrast to its impact on neutro-
philic inflammation, the concentration of TNF-α was
not associated with eosinophilic inflammation in this
study. Unlike neutrophils, eosinophilic inflammation
in asthma may be largely dependent on the ordinary
mediators involved in allergic inflammation including
Th2 cytokines, CC-chemokines and cysteinyl leukot-
rienes, and therefore the contributing role of TNF-α
may be limited.
The fact that concentrations of TNF-α and MPO
are weakly but positively correlated in healthy sub-
jects was not what we expected. This may suggest
that TNF-α may be a fundamental mechanism which
may be associated with activation of neutrophils in
the airways of healthy subjects . Interestingly , al-
though the reason is unclear, such a correlation be-
tween TNF-α and MPO was not observed in the mild
asthma group. In the mild asthma group, the concen-
tration of TNF-α was low, although it was not signifi-
cant (Fig. 1B). The cellular sources for providing
TNF-α to the airways can be a variety of cells includ-
ing eosinophils , 19 epithelial cells , 20 airway macro-
phages , 21 mast cells , 22 and neutrophils by them-
selves . 15 These mild asthma cases were well con-
trolled with low-dose inhalational corticosteroids, and
therefore it is possible that generation of inflamma-
tory cytokines including TNF-α may be effectively
suppressed. On the other hand, in severe asthma, in-
flammatory cells including increased neutrophils ,
which are insensitive to corticosteroids, may be, at
least in part, contributing sources of TNF-α in the air-
ways.
Taken together , the present study suggests that
TNF-α is an involved molecule for neutrophilic in-
flammation seen with severe asthma. Although the
clinical significance of neutrophilic inflammation in
severe asthma remains to be elucidated, this study
may provide important novel information about the
pathophysiology of severe asthma and a possible
therapeutic target, namely TNF-α, for controlling the
particular phenotype of the disease.
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